Solid lipid nanoparticles in cancer therapy
Keywords:
Cancer therapy, Solid lipid nanoparticles, Quantum dotsAbstract
The use of solid lipid nanoparticles in medicine and more specifically drug delivery is set to spread rapidly. Currently many substances are under investigation for drug delivery and more specifically for cancer therapy technology is the latest trend in the cancer therapy. It helps the pharmacist to formulate the product with maximum therapeutic value and minimum or negligible range side effects. Cancer is a class of disorders characterized by abnormal growth of cells that proliferate in an uncontrolled way and a major disadvantage of anticancer drugs is their lack of selectivity for tumor tissue, which causes severe side effects and results in low cure rates. Thus, it is very hard to target the abnormal cells by the conventional method of the drug delivery system. In harmony with these approaches, this review’s basic approach is that the defining features of solid lipid nanoparticles are embedded in their breakthrough potential for patient care. This review article describes the possible way to exploit solid lipid nanoparticle technology to targeted drug therapy in cancer. We looked at the usefulness of solid lipid nanoparticles as a tool for cancer therapy.
References
Mehnert W, Mader K. Solid lipid nanoparticles.
Production, characterization and applications. Adv
Drug Del Res 2001;47:165–96.
Muller RH, Keck CM. Challenges and solutions for
the delivery of biotech drugs – a review of drug
nanocrystal technology and lipid nanoparticles. J
Biotech 2004;113:151–70.
Castelli F et al. Characterization of indomethacinloaded lipid nanoparticles by differential scanning
calorimetry. Int J Pharm 2005;304:231–38.
Siekmann B, Westesen K. Submicron-sized
parenteral carrier systems based on solid lipids.
Pharm Pharmacol Lett 1992;1:123–6.
Manjunath K, Venkateswarlu V. Pharmacokinetics,
tissue distribution and bioavailability of clozapine
solid lipid nanoparticles after intravenous and
intraduodenal administration. J Control Release
;107:215–28.
Muller RH et al. Solid lipid nanoparticles (SLN) for
controlled drug delivery - a review of the state of
the art. Eur J Pharm Biopharm 2000;50:161–77.
Müller RH et al. Solid lipid nanoparticles (SLN)
and nanostructured lipid carriers (NLC) in cosmetic
and dermatological preparations. Adv Drug Deliv
Rev 2002;54: S131–55.
Müller RH et al. Nanostructured lipid matrices for
improved microencapsulation of drugs. Int J Pharm
;242:121–8.
Heurtault B et al. Physico-chemical stability of
colloidal lipid particles. Biomaterials
;24:4283–300.
Yang L et al. Estimates of cancer incidence in
China for 2000 and projections for 2005. Cancer
Epidemiol Biomarkers Prev 2005;14:243–250.
Bartsch M et al. Stabilized lipid coated lipoplexes
for the delivery of antisense oligonucleotides to
liver endothelial cells in vitro and in vivo. J Drug
Target 2004;12:613–21.
Bevers TB. Breast cancer chemoprevention: current
clinical practice and future direction. Biomed
Pharmacother 2001;55:559–564.
Harris AL et al. Mechanisms of multidrug
resistance in cancer treatment. Acta Oncol
;31:205–213.
Galmarini CM, Galmarini FC. Multidrug resistance
in cancer therapy: role of the microenvironment.
Curr Opin Invest Drug 2003; 4:1415–1421.
Gottesman MM et al. Multidrug resistance in
cancer: role of ATP-dependent transporters. Nat
Rev Cancer 2002;2:48–58.
Kellen JA. The reversal of multidrug resistance: an
update. J Exp Ther Oncol 2003;3:5–13.
Bradley G et al. Mechanism of multidrug
resistance. Biochem Biophys Acta 1988;948: 87–
Yang T et al. Enhanced solubility and stability of
PEGylated liposomal paclitaxel: in vitro and in
vivo evaluation. Int J Pharm 2007;338:317–326.
Jemal A et al. Cancer statistics, 2006. CA Cancer J
Clin 2006;56:106–30.
Jain A et al. Design and development of ligandappended polysaccharidic nanoparticles for the
delivery of oxaliplatin in colorectal cancer.
Nanomedicine: Nanotechnology, Biology, and
Medicine 2009;6:179-90.
Kumar R. Nano and microparticles as controlled
drug delivery devices. J Pharm Pharmaceut Sci
;3:234–258.
Nielsen D et al. Cellular resistance to
anthracyclines. Gen Pharmacol 1996; 27: 251–255.
Gasco MR. Solid lipid nanospheres from warm
micro-emulsions. Pharm Technol Eur 1997;9:52–
Cavalli R et al. Duodenal administration of solid
lipid nanoparticles loaded with different
percentages of tobramycin. J Pharm Sci
;92:1085–1094.
Gasco MR. Solid lipid nanoparticles for drug
delivery. Pharm Technol Eur 2001;13;32–41.
Parker SL et al. Cancer statistics. CA Cancer J Clin
;47:5–27.
Bonomi P. Review of selected randomized trials in
small cell lung cancer. Semin Oncol 1998;25:70–
Johnson BE et al. Risk of second aerodigestive
cancers increases in patients who survive free of
small-cell lung cancer for more than 2 years. J Clin
Oncol 1995;13:101–111.
Sidransky D, Hollstein M. Clinical implications of
the p53 gene. Annu Rev Med 1996;47:285–301
Takahashi T et al. Wild-type but not mutant p53
suppresses the growth of human lung cancer cells
bearing multiple genetic lesions. Cancer Res
;52:2340–2343.
Nemunaitis J. Adenovirus-mediated p53 gene
transfer in sequence with cisplatin to tumors of
patients with non-small-cell lung cancer. J Clin
Oncol 2000;18:609–622.
Bennett WP et al. p53 protein accumulates
frequently in early bronchial neoplasia. Cancer Res
;53:4817–4822.
Panyam J, Labhasetwar V. Biodegradable
nanoparticles for drug and gene delivery to cells
and tissue. Adv Drug Deliv Rev 2003;55:329–347.
Li SD, Huang L. Non-viral is superior to viral gene
delivery. J Control Rel 2007;123:181–183.
Mundargi RC et al. Nano/micro technologies for
delivering macromolecular therapeutics using
poly(d,l-lactide-co-glycolide) and its derivatives. J
Control Rel 2008;125:193– 209.
Singh M et al. Cationic microparticles: a potent
delivery system for DNA vaccines. Proc Natl Acad
Sci USA 2000;97:811–816.
Singh M et al. A modified process for preparing
cationic polylactide-co-glycolide microparticles
with adsorbed DNA. Int J Pharm 2006;327:1–5
Gohla SH, Dingler A, Scaling up feasibility of the
production of solid lipid nanoparticles (SLN).
Pharmazie 2001;56:61–63.
Zou Y et al. Effective treatment of early
endobronchial cancer with regional administration
of liposome-p53 complexes. J Natl Cancer Inst
;90:1130–1137.
Xu L et al. Tumor-targeted p53-gene therapy
enhances the efficacy of conventional
chemo/radiotherapy. J Control Release
;4:115–128.
Kim CK et al. Enhanced p53 gene transfer to
human ovarian cancer cells using the cationic
nonviral vector, DDC. Gynecol. Oncol
;90:265–272.
Lee CH et al. Synergistic effect of
polyethylenimine and cationic liposomes in nucleic
acid delivery to human cancer cells. Biochim
Biophys Acta 2003;1611:55–62.
Muller RH et al. Solid lipid nanoparticles (SLN) for
controlled drug delivery - a review of the state of
the art. Eur J Pharm Biopharm 2000;50:161–77.
Nagayama S et al. Time-dependent changes in
opsonin amount associated on nanoparticles alter
their hepatic uptake characteristics. Int J Pharm
;342:215–21.
Wissing SA et al. Solid lipid nanoparticles for
parenteral drug delivery. Adv Drug Deliv Rev
;56:1257–72.
Kreuter J. Influence of the surface properties on
nanoparticle-mediated transport of drugs to the
brian. J Nanosci Nanotechnol 2004;4:484–8.
CBTRUS, Statistical Report: Primary Brain
Tumors in the United States, 1998–2002. Central
Brain Tumor Registry of the United States:2005.
ACS. Cancer Facts & Figures 2004, American
Cancer Society:2004.
SEER CDC data:
http://www.cdc.gov/cancer/natlcancerdata.htm
(accessed 2 March 2010)
Zimmer C et al. MR imaging of phagocytosis in
experimental gliomas. Radiology 1995;197:533–8.
Vasir JK et al. Nanosystems in Drug Targeting:
Opportunities and Challenges. Curr Nanosci
;1:47–64.
Vijayaraghavalu S et al. Nanoparticles for delivery
of chemotherapeutic agents to tumors. Curr Opin
Investig Drugs 2007;8:477–84.
Wang X et al. Anti-PEG IgM elicited by injection
of liposomes is involved in the enhanced blood
clearance of a subsequent dose of PEGylated
liposomes. J Control Release. 2007;119:236–44.
Olivier JC et al. Indirect evidence that drug brain
targeting using polysorbate 80-coated
polybutylcyanoacrylate nanoparticles is related to
toxicity. Pharm Res 1999;16:1836–42.
Kreuter J et al. Direct evidence that polysorbate-80-
coated poly(butylcyanoacrylate) nanoparticles
deliver drugs of the CNS via specific mechanisms
requiring prior binding of drug to the nanoparticles.
Pharm Res 2003;20:409–16.
Lockman PR et al. In vivo and in vitro assessment
of baseline blood-brain-barrier parameters in the
presence of novel nanoparticles. Pharm Res
;20:705–13.
Elder A et al. Translocation of inhaled ultrafine
manganese oxide particles to the central nervous
system. Environ Health Perspect 2006;114:1172–8.
Runge S et al. SLN (solid lipid nanoparticles), a
novel formulation for the oral administration of
drugs. Eur J Pharm Sci 1996;4:S132.
Ponchel G et al. Mucoadhesion of colloidal
particulate systems in the gastro-intestinal tract. Eur
J Pharm Biopharm 1997;44:25–31.
Pinto JF, Müller RH. Pellets as carriers of solid
lipid nanoparticles (SLN) for oral administration of
drugs. Pharmazie 1999;54:506–9.
Müller RH et al. Biodegradation of solid lipid
nanoparticles as a function of lipase incubation
time. Int J Pharm 1996b;144:115–21
Freitas C, Müller RH. Spray-drying of solid lipid
nanoparticles (SLN™). Eur J Pharm Biopharm
;46:145–51.
Jani PU et al. Nanoparticle uptake by the rat
gastrointestinal mucosa: quantitation and particle
size dependency. J Pharm Pharmacol 1990;42:821–
Nishiyama N, Kataoka K. Current state,
achievements, and future prospects of polymeric
micelles as nanocarriers for drug and gene delivery.
Pharmacol Ther 2006;112:630–648.
Vicent MJ, Duncan R. Polymer conjugates:
nanosized medicines for treating cancer. Trends in
biotechnology 2006;24:39–47.
Portney NG, Ozkan M. Nano-oncology: drug
delivery, imaging, and sensing. Anal Bioanal Chem
;384:620–630.
Leary SP et al. Toward the emergence of
nanoneurosurgery: part II--nanomedicine:
diagnostics and imaging at the nanoscale level.
Neurosurgery 2006;58:805–23.
Giepmans BN et al. The fluorescent toolbox for
assessing protein location and function. Science
;312:217–224.
Pinaud F et al. Advances in fluorescence imaging
with quantum dot bio-probes. Biomaterials
;27:1679–1687.
Juzenas P et al. Quantum dots and nanoparticles for
photodynamic and radiation therapies of cancer.
Adv Drug Deliv Rev 2008;60:1600–1614.
Leary SP et al. Toward the Emergence of
Nanoneurosurgery: Part III-Nanomedicine:
Targeted Nanotherapy, Nanosurgery, and Progress
Toward the Realization of Nanoneurosurgery.
Neurosurgery 2006;58:1009–1026.
McDevitt MR et al. Tumor therapy with targeted
atomic nanogenerators. Science 2001;294:1537–
Hirsch LR et al. Nanoshell-mediated near-infrared
thermal therapy of tumors under magnetic
resonance guidance. Proc Natl Acad Sci USA 2003;
: 13549–13554.
Wong JYC. Systemic targeted radionuclide
therapy: Potential new areas. Int J Radiat Oncol
Biol Phys 2006;66:S74–S82.
Dearling JLJ, Pedley RB. Technological advances
in radioimmunotherapy. Clin Oncol 2007;19:457–
Paganelli G et al. IART(R): Intraoperative
avidination for radionuclide treatment. A new way
of partial breast irradiation. The Breast
;16:17–26.
Corot C et al. Recent advances in iron oxide
nanocrystal technology for medical imaging. Adv
Drug Deliv Rev 2006;58:1471–1504.
Pankhurst QA et al. Applications of magnetic
nanoparticles in biomedicine. J Physics D-Applied
Physics 2003; 36: R167–R181.
Dobson J. Magnetic nanoparticles for drug
delivery. Drug Dev Res 2006;67:55–60.
Senyei A et al. Magnetic guidance of drug-carrying
microspheres. J Applied Physics 1978;49:3578–
Neuberger T et al. Superparamagnetic nanoparticles
for biomedical applications: Possibilities and
limitations of a new drug delivery system. Journal
Of Magnetism And Magnetic Materials
;293:483–496.
Torchilin VP. Multifunctional nanocarriers. Adv
Drug Deliv Rev 2006;58:1532–55.
Zhang Y et al. Surface modification of
superparamagnetic magnetite nanoparticles and
their intracellular uptake. Biomaterials
;23:1553–1561.
Veiseh O et al. Optical and MRI multifunctional
nanoprobe for targeting gliomas. Nano Letters
;5:1003–1008.
Huh YM et al. In vivo magnetic resonance
detection of cancer by using multifunctional
magnetic nanocrystals. J Am Chem Soc
;127:12387–91.
Harisinghani MG et al. Noninvasive detection of
clinically occult lymphnode metastases in prostate
cancer. N Engl J Med 2003;348:2491–99.
Semelka RC, Helmberger TK. Contrast agents for
MR imaging of the liver. Radiology 2001;218:27–
Enochs WS et al. Improved delineation of human
brain tumors on MR images using a longcirculating, superparamagnetic iron oxide agent. J
Magn Reson Imaging 1999;9:228–32.
Neuwelt EA et al. Imaging of iron oxide
nanoparticles by MR and light microscopy in
patients with malignant brain tumours. Neuropathol
Appl Neurobiol 2004;30:456–71.
